OMNIQ Corp. (NASDAQ:OMQS) ("OMNIQ" or "the Company"), a provider of Artificial Intelligence (AI)-based solutions, today announced that the Company has been selected by the Cities of
OMNIQ (NASDAQ:OMQS) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.31) by 67.74 percent. This is a 28.77 percent increase over losses of $(0.73) per share from the same
Companies Reporting Before The Bell
• Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
This order follows the recent announcements of projects and purchase orders including the receipt of a $29 Million project for supply chain equipment from a Fortune 100 corporation, the award of an $11
A five year supply agreement for Intelligent Healthcare Carts to be deployed in over 20 Prestigious Medical Centers.
Dynamic Computer Solution includes Sensors, Automated Patient Identification, Diagnostic
OMNIQ (NASDAQ:OMQS) brought in sales totaling $24.21 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 24.02%, resulting in a loss of $3.19 million.
Benzinga Pro data, OMNIQ (NASDAQ:OMQS) reported Q2 sales of $24.21 million. Earnings fell to a loss of $3.19 million, resulting in a 24.02% decrease from last quarter.
OMNIQ’s 2022 continuous momentum:
54% growth in 6 month Revenue marks an all-time record of over $50 Million.
104% growth in 6 Month Gross Profit up to a record of over $12M.
85% Growth in Q2 Revenue compared